Tudor Oprea, MD, PhD
Department of Internal Medicine
Division of Translational Informatics
UNM Cancer Center Position(s)
Bioinformatics and High-Dimensional Data Analysis Shared Resource co-Director
Cancer Therapeutics: Technology, Discovery and Targeted Delivery
I am a data scientist with interests in knowledge management applied to target and drug discovery, translational bioinformatics, target and drug repurposing, and health-record analytics. At AstraZeneca, I conceptually developed the lead-like approach for combinatorial chemistry and fragment-based drug discovery. My in silico drug repurposing work at UNM led to anti-cancer clinical trials for Raltegravir (NCT01275183; as metnase inhibitor) and Ketorolac (NCT01670799; as Rac1/Cdc42 inhibitor). As Guest Professor in Denmark, I assisted with data analytics of the Danish National Population Health Registry, 6.2 million patients over a 15-year period. As Visiting Professor in Gothenburg, Sweden, I have provided support to a phagocyte-centered group since 2012, specifically concerning receptor modulated chemotaxis and immunomodulation. I have been developing machine learning models since 1989, initially in chemical informatics, more recently in computational biology and medicine. To date, I have co-authored over 180 publications and 8 granted US patents. My team routinely processes and integrates data related to genes, drugs, proteins, pathways, cells, tissues and clinical records from literature and patents, from drug labels and clinical trials, and from large scale experiments in order to properly map proteins, drugs and diseases. We have an adaptive, scalable and evolving knowledge mining system dedicated to human disease biology, drug discovery and repurposing. I am the PI for the NIH Common Fund project "Illuminating the Druggable Genome Knowledge Management Center“ (U54 CA189205, 8/1/14 – 12/31/17; and U24 CA224370, 1/01/18 – 12/31/23). In this role I coordinate knowledge management efforts across multiple levels, from tissue expression and protein function to role in disease and target prioritization for experiments and drug discovery. The KMC has developed four websites in support of IDG activities, and maintains dedicated IDG resources since 2014. Specifically, for the Comprehensive Cancer Center Support Grant, I will assist with the computational pipeline development for target and drug discovery and repurposing, including data aggregation, model interpretation, patent informatics and project prioritization.